| Detection of various microplastics in human stool: a prospective case series P Schwabl, S Köppel, P Königshofer, T Bucsics, M Trauner, T Reiberger, ... Annals of internal medicine 171 (7), 453-457, 2019 | 1286 | 2019 |
| Assessment of microplastic concentrations in human stool: Final results of a prospective study B Liebmann, S Köppel, P Königshofer, T Bucsics, T Reiberger, P Schwabl Conference on nano and microplastics in technical and freshwater systems, 28-31, 2018 | 88 | 2018 |
| The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model P Schwabl, E Hambruch, GR Budas, P Supper, M Burnet, JT Liles, ... Biomedicines 9 (1), 60, 2021 | 47 | 2021 |
| Assessment of microplastic concentrations in human stool-Preliminary results of a prospective study P Schwabl, B Liebmann, S Köppel, P Königshofer, T Bucsics, M Trauner, ... United European Gastroenterol J 6 (Supplement 1), 2018 | 46 | 2018 |
| The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats P Schwabl, K Brusilovskaya, P Supper, D Bauer, P Königshofer, F Riedl, ... Scientific Reports 8 (1), 9372, 2018 | 45 | 2018 |
| Animal models of portal hypertension P Königshofer, K Brusilovskaya, P Schwabl, T Reiberger Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1865 (5 …, 2019 | 35 | 2019 |
| Nuclear receptors in liver fibrosis P Königshofer, K Brusilovskaya, O Petrenko, BS Hofer, P Schwabl, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1867 (12), 166235, 2021 | 29 | 2021 |
| Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies P Königshofer, BS Hofer, K Brusilovskaya, B Simbrunner, O Petrenko, ... Hepatology 75 (3), 610-622, 2022 | 27 | 2022 |
| Vascular targets for the treatment of portal hypertension K Brusilovskaya, P Königshofer, P Schwabl, T Reiberger Seminars in Liver Disease 39 (04), 483-501, 2019 | 24 | 2019 |
| Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct–ligated rats K Brusilovskaya, P Königshofer, D Lampach, A Szodl, P Supper, D Bauer, ... United European Gastroenterology Journal 8 (10), 1174-1185, 2020 | 23 | 2020 |
| Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease B Simbrunner, IF Villesen, P Königshofer, B Scheiner, D Bauer, ... Liver International 42 (11), 2501-2512, 2022 | 19 | 2022 |
| Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response B Simbrunner, E Caparrós, T Neuwirth, P Schwabl, P Königshofer, ... Hepatology International 17 (4), 1045-1056, 2023 | 11 | 2023 |
| Recent advances in practical methods for liver cell biology: a short overview S Torres, Z Abdullah, MJ Brol, C Hellerbrand, M Fernandez, R Fiorotto, ... International journal of molecular sciences 21 (6), 2027, 2020 | 11 | 2020 |
| Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension P Schwabl, BA Seeland, F Riedl, TL Schubert, P Königshofer, ... Advances in Medical Sciences 67 (1), 154-162, 2022 | 7 | 2022 |
| Invasive hemodynamic characterization of the portal-hypertensive syndrome in cirrhotic rats P Königshofer, K Brusilovskaya, P Schwabl, BK Podesser, M Trauner, ... JoVE (Journal of Visualized Experiments), e57261, 2018 | 7 | 2018 |
| GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/-Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling CD Fuchs, T Claudel, V Mlitz, A Riva, M Menz, K Brusilovskaya, F Haller, ... Cellular and Molecular Gastroenterology and Hepatology 16 (5), 847-856, 2023 | 5 | 2023 |
| The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model. Biomedicines. 2021; 9 (1): 60 P Schwabl, E Hambruch, GR Budas, P Supper, M Burnet, JT Liles, ... s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …, 2021 | 4 | 2021 |
| Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension O Petrenko, P Königshofer, K Brusilovskaya, BS Hofer, K Bareiner, ... Iscience 27 (3), 2024 | 1 | 2024 |
| Targeting the nitric-oxide downstream pathway in bile-duct ligated rats to improve portal hypertension and liver fibrosis K Brusilovskaya, P Königshofer, D Lampach, A Szodl, P Supper, ... Journal of Hepatology 68, S9, 2018 | 1 | 2018 |
| THU-540 Characterization of in vivo mouse models of regressive fibrosis and resolving portal hypertension K Bonitz, P Königshofer, B Hofer, O Petrenko, T Sorz, V Taru, ... Journal of Hepatology 80, S267, 2024 | | 2024 |
